137 related articles for article (PubMed ID: 38892177)
1. High-Yield α-Synuclein Purification and Ionic Strength Modification Pivotal to Seed Amplification Assay Performance and Reproducibility.
Janarthanam C; Clabaugh G; Wang Z; Melvin BR; Scheibe I; Jin H; Anantharam V; Urbauer RJB; Urbauer JL; Ma J; Kanthasamy A; Huang X; Donadio V; Zou W; Kanthasamy AG
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892177
[TBL] [Abstract][Full Text] [Related]
2. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
Russo MJ; Orru CD; Concha-Marambio L; Giaisi S; Groveman BR; Farris CM; Holguin B; Hughson AG; LaFontant DE; Caspell-Garcia C; Coffey CS; Mollon J; Hutten SJ; Merchant K; Heym RG; Soto C; Caughey B; Kang UJ
Acta Neuropathol Commun; 2021 Nov; 9(1):179. PubMed ID: 34742348
[TBL] [Abstract][Full Text] [Related]
3. Accurate Detection of α-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.
Concha-Marambio L; Weber S; Farris CM; Dakna M; Lang E; Wicke T; Ma Y; Starke M; Ebentheuer J; Sixel-Döring F; Muntean ML; Schade S; Trenkwalder C; Soto C; Mollenhauer B
Mov Disord; 2023 Apr; 38(4):567-578. PubMed ID: 36781413
[TBL] [Abstract][Full Text] [Related]
4. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden.
Bentivenga GM; Mammana A; Baiardi S; Rossi M; Ticca A; Magliocchetti F; Mastrangelo A; Poleggi A; Ladogana A; Capellari S; Parchi P
Acta Neuropathol; 2024 Jan; 147(1):18. PubMed ID: 38240849
[TBL] [Abstract][Full Text] [Related]
5. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
[TBL] [Abstract][Full Text] [Related]
6. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.
Srivastava A; Alam P; Caughey B
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454165
[TBL] [Abstract][Full Text] [Related]
7. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid.
Concha-Marambio L; Pritzkow S; Shahnawaz M; Farris CM; Soto C
Nat Protoc; 2023 Apr; 18(4):1179-1196. PubMed ID: 36653527
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders.
Fernandes Gomes B; Farris CM; Ma Y; Concha-Marambio L; Lebovitz R; Nellgård B; Dalla K; Constantinescu J; Constantinescu R; Gobom J; Andreasson U; Zetterberg H; Blennow K
Parkinsonism Relat Disord; 2023 Dec; 117():105807. PubMed ID: 37591709
[TBL] [Abstract][Full Text] [Related]
9. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.
Shahnawaz M; Tokuda T; Waragai M; Mendez N; Ishii R; Trenkwalder C; Mollenhauer B; Soto C
JAMA Neurol; 2017 Feb; 74(2):163-172. PubMed ID: 27918765
[TBL] [Abstract][Full Text] [Related]
10. Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms.
Röntgen A; Toprakcioglu Z; Tomkins JE; Vendruscolo M
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2313465121. PubMed ID: 38324572
[TBL] [Abstract][Full Text] [Related]
11. Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage.
Majbour N; Aasly J; Abdi I; Ghanem S; Erskine D; van de Berg W; El-Agnaf O
Neurology; 2022 Nov; 99(21):e2417-e2427. PubMed ID: 36096686
[TBL] [Abstract][Full Text] [Related]
12. A short motif in the N-terminal region of α-synuclein is critical for both aggregation and function.
Doherty CPA; Ulamec SM; Maya-Martinez R; Good SC; Makepeace J; Khan GN; van Oosten-Hawle P; Radford SE; Brockwell DJ
Nat Struct Mol Biol; 2020 Mar; 27(3):249-259. PubMed ID: 32157247
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism.
Choong CJ; Aguirre C; Kakuda K; Beck G; Nakanishi H; Kimura Y; Shimma S; Nabekura K; Hideshima M; Doi J; Yamaguchi K; Nakajima K; Wadayama T; Hayakawa H; Baba K; Ogawa K; Takeuchi T; Badawy SMM; Murayama S; Nagano S; Goto Y; Miyanoiri Y; Nagai Y; Mochizuki H; Ikenaka K
Acta Neuropathol; 2023 May; 145(5):573-595. PubMed ID: 36939875
[TBL] [Abstract][Full Text] [Related]
14. Defining the native state of α-synuclein.
Selkoe D; Dettmer U; Luth E; Kim N; Newman A; Bartels T
Neurodegener Dis; 2014; 13(2-3):114-7. PubMed ID: 24192542
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis.
Yoo D; Bang JI; Ahn C; Nyaga VN; Kim YE; Kang MJ; Ahn TB
Parkinsonism Relat Disord; 2022 Nov; 104():99-109. PubMed ID: 36289019
[TBL] [Abstract][Full Text] [Related]
16. N-Terminal Acetylation Affects α-Synuclein Fibril Polymorphism.
Watson MD; Lee JC
Biochemistry; 2019 Sep; 58(35):3630-3633. PubMed ID: 31424918
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α-Synuclein in the Context of Co-Pathology and Non-LBD Diagnoses.
Arnold MR; Coughlin DG; Brumbach BH; Smirnov DS; Concha-Marambio L; Farris CM; Ma Y; Kim Y; Wilson EN; Kaye JA; Hiniker A; Woltjer RL; Galasko DR; Quinn JF
Ann Neurol; 2022 Oct; 92(4):650-662. PubMed ID: 35808984
[TBL] [Abstract][Full Text] [Related]
18. Blinded RT-QuIC Analysis of α-Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients.
Manne S; Kondru N; Jin H; Serrano GE; Anantharam V; Kanthasamy A; Adler CH; Beach TG; Kanthasamy AG
Mov Disord; 2020 Dec; 35(12):2230-2239. PubMed ID: 32960470
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
20. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
